Trypsin inhibitors: promising candidate satietogenic proteins as complementary treatment for obesity and metabolic disorders?

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
Insulin 3 endocrinologydiseasesdrugs
Liraglutide 1 endocrinologydiseasesdrugs
diabetes mellitus 1 endocrinologydiseases
hyperglycemia 2 endocrinologydiseases
metabolic syndrome 8 endocrinologydiseases
obesity 43 endocrinologydiseases
orlistat 1 endocrinologydiseasesdrugs
type 2 diabetes mellitus 1 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Insulin 15041 (CCK) and leptin, which signal the reduction of hunger in the brain and promote cessation of the meal. Insulin , a pancreatic hormone, also plays an important role in human metabolism and in eating behaviour[47].Metabolic
Insulin 18298 is co-expressed with the CCKR1 receptors, generating a cooperative effect between leptin and CCK[56]. Insulin is also related to body adiposity. Like leptin, the insulin produced is transported to the brain, and
Insulin 18474 is transported to the brain, and its direct administration in that tissue reduces food intake[57]. Insulin , similar to leptin, also has a synergistic effect on CCK. CCK is capable of increasing insulin transport
Liraglutide 7680 steatorrhea and fecal incontinence caused by orlistat are the main cause of discontinuation of treatment. Liraglutide is an agonist of intestinal hormones peptide-1 (GLP-1) used in the treatment of diabetes but also reduces
orlistat 7619 digestion and intestinal absorption of fats. Flatulence, steatorrhea and fecal incontinence caused by orlistat are the main cause of discontinuation of treatment. Liraglutide is an agonist of intestinal hormones
Select Disease Character Offset Disease Term Instance
diabetes mellitus 5963 lipid profile and insulin resistance. The risks of coronary heart disease, ischemic stroke, and type 2 diabetes mellitus increase linearly with increased body mass index (BMI)[21]. The presence of overweight and/or obesity
hyperglycemia 45136 charantia Linn), a widely consumed vegetable in subtropical regions, showed properties of control of hyperglycemia . Bitter gourd was already used in folk medicine for this purpose, but this fact was proven by the interaction
hyperglycemia 53078 carbohydrates (about 60% of total energy), induce weight gain, increased body fat deposition, triglycerides, hyperglycemia , inflammation, and hyperleptinemia[88],[91]. Performance responses may also vary due to the nutritional
metabolic syndrome 572 diseases has aroused interest in the research of adjuvants to the classic forms of treatments. Obesity and metabolic syndrome are the main targets of confrontation because they relate directly to other chronic diseases. In this
metabolic syndrome 1173 thus, emerging as potential candidates and promising molecules in the treatment of the obesity and metabolic syndrome . Thus, the present article proposes to approach, through a systematic literature review, the advantages,
metabolic syndrome 6200 coexistence of metabolic alterations of different NCD, an increasingly common condition denominated metabolic syndrome [3].Up to 80% of NCD deaths can be avoided with known behavioural and pharmaceutical interventions. Several
metabolic syndrome 39746 weight, biochemical and inflammatory parameters.Adult male Wistar rats (n = 05) with obesity and metabolic syndrome . Obesity was induced by high glycemic index and glycemic load diet.A diet with high glicemic index and
metabolic syndrome 43397 studies.Trypsin inhibitors in the treatment of chronic diseases: challenges and future prospectsObesity and the metabolic syndrome are conditions that lead to an extensive metabolic dysregulation. Excessive accumulation of adipose
metabolic syndrome 48384 adipose tissue[83].Tamarind trypsin inhibitor when administered by gavage in Wistar rats with obesity and metabolic syndrome induced by diet, besides causing the reduction of the food consumption in these animals, also reduced
metabolic syndrome 48652 loss[16]. TNF-alpha is recognized as a central inflammatory cytokine in the inflammatory response of the metabolic syndrome and obesity[84].Subsequent studies involving the trypsin inhibitor of tamarind seeds, isolated[72] and
metabolic syndrome 52587 model has been a necessity[90].Because it is one of the main factors for the development of obesity and metabolic syndrome , the development of diets that reproduce pathophysiological findings in humans has been sought. The
obesity 152 ChemistryTrypsin inhibitors: promising candidate satietogenic proteins as complementary treatment for obesity and metabolic disorders?Alternative Title: V. Cristina Oliveira de Lima et al.Vanessa Cristina Oliveira
obesity 827 molecules with wide heterologous application, appear as possibilities in the treatment of overweight and obesity due to the action on satiety related mechanisms, mainly in the modulation of satiety hormones, such
obesity 1161 these diseases, thus, emerging as potential candidates and promising molecules in the treatment of the obesity and metabolic syndrome. Thus, the present article proposes to approach, through a systematic literature
obesity 1405 disadvantages and viabilities for the use of trypsin inhibitors directed to the treatment of overweight and obesity .IntroductionOverweight and obesity have increased the prevalence of non-communicable chronic diseases
obesity 1440 of trypsin inhibitors directed to the treatment of overweight and obesity.IntroductionOverweight and obesity have increased the prevalence of non-communicable chronic diseases (NCDs), putting this problem at a
obesity 3387 the potential of these molecules in the treatment of chronic diseases associated to overweight and obesity [8]. Although the number of molecules tested in experimental models of obesity and food behaviour is
obesity 3465 associated to overweight and obesity[8]. Although the number of molecules tested in experimental models of obesity and food behaviour is still small, trypsin inhibitors have shown to be a promising alternative and capable
obesity 3761 importance of discussing the use of new adjuvants in the supplementary treatment of overweight and obesity , the present article proposes to approach through an attempt to systematically review of the advantages,
obesity 4256 selecting those that involved the use of trypsin inhibitors in food consumption, body weight, satiety, obesity and other related metabolic parameters.The impacts of obesityNCDs are emerging as the greatest public
obesity 4318 food consumption, body weight, satiety, obesity and other related metabolic parameters.The impacts of obesity NCDs are emerging as the greatest public health challenge of the early 21st century. Environmental changes
obesity 5697 in lifestyle resulting from the processes of urbanization and globalization[20].Thus, overweight and obesity stand out as potential causes of other NCDs. Overweight and obesity, the latter, classified as a NCD,
obesity 5765 globalization[20].Thus, overweight and obesity stand out as potential causes of other NCDs. Overweight and obesity , the latter, classified as a NCD, lead to adverse metabolic effects on blood pressure, lipid profile
obesity 6075 mellitus increase linearly with increased body mass index (BMI)[21]. The presence of overweight and/or obesity makes common the coexistence of metabolic alterations of different NCD, an increasingly common condition
obesity 6660 targets for reducing NCD mortality in all nations by one third by 2030[22].The continued increase in obesity , hypertension, and diabetes shows the inadequacy of current strategies and raises the challenge of implementing
obesity 7456 the preexisting cardiovascular disease. Orlistat, another drug popularly known in the treatment of obesity , is an inhibitor of pancreatic lipase, thus reducing digestion and intestinal absorption of fats. Flatulence,
obesity 15172 also plays an important role in human metabolism and in eating behaviour[47].Metabolic syndrome and obesity are NCDs generally associated with increased energy intake in relation to calorie requirements and delayed
obesity 15353 calorie requirements and delayed satiety. Since alterations in gastrointestinal motor functions in obesity may present useful targets for preventing and treating metabolic disorders, the management of gastric
obesity 19066 intake seems to be the most effective way to lose weight and improve glucose control in individuals with obesity or diabetes. However, attempts to sustain significant weight loss through lifestyle intervention often
obesity 25977 inhibitor[14].Subsequently, the same tamarind seed inhibitor was evaluated in Wistar rats with diet-induced obesity and given by gavage over a period of 10 days. No difference in weight gain was observed between TTI
obesity 26124 10 days. No difference in weight gain was observed between TTI and obese rats, both on diet-induced obesity . However, the rats treated with the inhibitor showed a consumption reduction significantly higher, indicating
obesity 26417 Carvalho et al.[16], Costa et al.[72] also evaluated the effect of TTI on an experimental model of obesity . It was observed that TTI was able to reduce food intake in animals submitted to an unbalanced diet,
obesity 28673 Table 1.Table 1.Results of the search in databases on trypsin inhibitors, satiety, food consumption and obesity .Trypsin inhibitorStudyAssessed parametersExperimental modelExperimental designResultsSynthetic Trypsin
obesity 29659 obese and lean rats, but with a greater response in obese rats. Reduction of body weight in rats with obesity , but not lean. These results were attributed to the effect of trypsin inhibitors on CCK.Soybean (SBTI/
obesity 39734 consumption, weight, biochemical and inflammatory parameters.Adult male Wistar rats (n = 05) with obesity and metabolic syndrome. Obesity was induced by high glycemic index and glycemic load diet.A diet with
obesity 42241 relative biases to the natural aging process of the animals[74]. Also, there is no standard for the obesity induction protocol.Relative to the molecule, it is known that CCK is a molecule associated with satiety
obesity 42444 satiety in the short term. The response to CCK can also be a confounding factor. Some diet-induced obesity , such as that induced by a hyperlipidic diet, alter sensitivity to CCK, whereas, in some animal models,
obesity 42611 sensitivity to CCK, whereas, in some animal models, the low sensitivity to CCK is a condition that preceds obesity [75]. Finally, the mechanism of satiety by the action of the inhibitors needs further clarification,
obesity 45660 several functional properties, mainly related to cardiovascular parameters, altered in overweight and obesity conditions, and in chronic diseases due to these conditions[79]. Studies related to the activity of
obesity 46785 β-conglycinin also demonstrates activity on the hepatic deposition of lipids. OLETF rats fed a sucrose-inducing obesity diet, in which β-conglycinin partially replaced the protein source, showed significant differences
obesity 47517 dietary intake of β-conglycinin has been shown to reverse some of the metabolic abnormalities related to obesity observed in OLETF mice. In particular, the hypolipogenic function of β-conglycinin in the liver may
obesity 47836 β-conglycine may have a potential effect on nonalcoholic hepatic steatosis, a common complication in obesity [82]. In the study by Li et al.[83], supplementation of male mice submitted to a hyperlipid diet induced
obesity 48372 subcutaneous adipose tissue[83].Tamarind trypsin inhibitor when administered by gavage in Wistar rats with obesity and metabolic syndrome induced by diet, besides causing the reduction of the food consumption in these
obesity 48675 recognized as a central inflammatory cytokine in the inflammatory response of the metabolic syndrome and obesity [84].Subsequent studies involving the trypsin inhibitor of tamarind seeds, isolated[72] and purified[17]
obesity 48864 isolated[72] and purified[17] these proteins administering them by gavage in Wistar rats with diet-induced obesity , evaluating its action on CCK and leptin. At both stages of purification, in both studies, the inhibitor
obesity 49060 studies, the inhibitor was able to reduce serum leptin concentrations five-fold compared to the untreated obesity group.Purification of an inhibitor extracted from natural sources is an important step since its activity
obesity 51690 CCK1R gene expression[88]. The reduction of leptin concentrations, known to be high in individuals with obesity , may be essential for the improvement of sensitivity to this hormone, as well as CCK since they share
obesity 52157 Working with animal models is imperative, especially with a species that shares characteristics of human obesity and its comorbidities. Although there is a clear and well-documented genetic component for the trend
obesity 52273 comorbidities. Although there is a clear and well-documented genetic component for the trend toward obesity , most cases of human obesity are still considered a result of the integrated activity of numerous genes
obesity 52302 is a clear and well-documented genetic component for the trend toward obesity, most cases of human obesity are still considered a result of the integrated activity of numerous genes and their relationship to
obesity 52575 animal model has been a necessity[90].Because it is one of the main factors for the development of obesity and metabolic syndrome, the development of diets that reproduce pathophysiological findings in humans
obesity 53266 also vary due to the nutritional status of the animal model and species. Moreover, it is known that in obesity different results may be observed when applying treatments as opposed to what is observed in situations
obesity 53440 opposed to what is observed in situations of eutrophy[94],[95].Studies involving trypsin inhibitors and obesity mostly direct administration of the inhibitors to the gastrointestinal tract. The submission of these
obesity 55352 stability of TTI[98].ConclusionDespite the challenges in prospecting for new molecules for the treatment of obesity , the results with trypsin inhibitors are promising. The different physiological effects of these molecules,
type 2 diabetes mellitus 5956 pressure, lipid profile and insulin resistance. The risks of coronary heart disease, ischemic stroke, and type 2 diabetes mellitus increase linearly with increased body mass index (BMI)[21]. The presence of overweight and/or obesity

You must be authorized to submit a review.